Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 10.63%26.13B | 5.55%23.62B | 17.06%7.2B | 9.76%6.44B | 0.90%5.31B | -8.39%4.67B | 7.18%22.37B | 13.92%6.15B | 1.97%5.86B | 6.06%5.26B |
| Cost of revenue | 11.08%15.36B | 8.03%13.83B | 13.03%4.16B | 23.60%3.81B | -1.64%2.99B | -4.28%2.87B | 7.71%12.8B | 20.39%3.68B | -8.83%3.08B | 11.60%3.04B |
| Gross profit | 10.00%10.77B | 2.24%9.79B | 23.05%3.05B | -5.57%2.63B | 4.39%2.31B | -14.26%1.8B | 6.48%9.57B | 5.52%2.48B | 17.38%2.78B | -0.71%2.22B |
| Operating expense | 11.29%8.18B | 6.00%7.35B | 3.54%1.92B | 9.08%2.01B | 7.37%1.76B | 3.87%1.65B | 13.67%6.93B | 18.07%1.85B | 14.84%1.84B | 15.48%1.64B |
| Staff costs | 7.68%3.3B | 9.20%3.06B | ---- | ---- | ---- | ---- | 12.89%2.8B | ---- | ---- | ---- |
| Selling and administrative expenses | 10.28%2.31B | -7.09%2.09B | ---- | ---- | ---- | ---- | 12.06%2.25B | ---- | ---- | ---- |
| -Selling and marketing expense | 29.17%497.24M | -13.96%384.94M | ---- | ---- | ---- | ---- | 16.46%447.39M | ---- | ---- | ---- |
| -General and administrative expense | 6.03%1.81B | -5.39%1.71B | ---- | ---- | ---- | ---- | 11.03%1.81B | ---- | ---- | ---- |
| Research and development costs | 40.67%692.49M | 23.20%492.29M | ---- | ---- | ---- | ---- | 8.74%399.59M | ---- | ---- | ---- |
| Depreciation and amortization | 7.80%457.92M | 57.20%424.79M | ---- | ---- | ---- | ---- | -7.17%270.23M | ---- | ---- | ---- |
| -Depreciation | 3.00%377.57M | 35.66%366.59M | ---- | ---- | ---- | ---- | -7.17%270.23M | ---- | ---- | ---- |
| -Amortization | 38.05%80.35M | --58.21M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Rent and land expenses | 4.56%291.35M | 29.75%278.64M | ---- | ---- | ---- | ---- | 19.14%214.74M | ---- | ---- | ---- |
| Other operating expenses | 13.34%1.13B | 0.69%1B | ---- | ---- | ---- | ---- | 29.31%993.61M | ---- | ---- | ---- |
| Operating profit | 6.12%2.59B | -7.65%2.44B | 81.16%1.13B | -34.35%616.01M | -4.17%550.11M | -71.53%143.62M | -8.70%2.64B | -19.87%622.52M | 22.69%938.36M | -29.14%574.06M |
| Net non-operating interest income (expenses) | -2.96%24.89M | 305.26%25.65M | 415.81%8.45M | 376.20%7.34M | 422.93%8.26M | 1.72%1.6M | -1.17%6.33M | 20.89%1.64M | -4.99%1.54M | 0.00%1.58M |
| Non-operating interest income | -2.96%24.89M | 305.26%25.65M | 415.81%8.45M | 376.20%7.34M | 422.93%8.26M | 1.72%1.6M | -1.17%6.33M | 20.89%1.64M | -4.99%1.54M | 0.00%1.58M |
| Net investment income | -203.42%-104.13M | -6.98%100.69M | 183.68%22.71M | -66.65%-32.74M | -60.69%7.61M | -24.00%103.11M | 5.46%108.24M | -142.48%-27.14M | -134.72%-19.65M | 273.76%19.35M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 77.61%-5.68M | -41.86%-25.34M | -105.31%-250K | 100.26%58K | 807.95%2.49M | -18,651.01%-27.64M | -124.46%-17.86M | 689.26%4.7M | -186,275.00%-22.37M | -101.99%-352K |
| Less:Other special charges | -77.61%5.68M | 41.86%25.34M | 105.31%250K | -100.26%-58K | -807.95%-2.49M | 18,651.01%27.64M | 124.46%17.86M | -689.26%-4.7M | 186,275.00%22.37M | 101.99%352K |
| Other non-operating income (expenses) | 20.76%27.68M | -30.57%22.92M | -56.42%5.85M | -304.42%-9.24M | 223.71%17.91M | -11.92%8.41M | 145.13%33.02M | 177.85%13.42M | 185.64%4.52M | -35.85%5.53M |
| Income before tax | -1.25%2.53B | -7.50%2.56B | 89.31%1.16B | -35.57%581.43M | -2.30%586.38M | -64.83%229.1M | -10.28%2.77B | -27.42%615.14M | 10.36%902.41M | -27.42%600.16M |
| Income tax | -3.10%775.24M | 1.22%800.01M | 46.31%367.84M | -6.42%183.56M | 8.40%159.74M | -54.53%88.87M | -17.02%790.35M | -29.46%251.41M | -8.78%196.15M | -32.96%147.37M |
| Net income | -0.41%1.75B | -10.99%1.76B | 119.03%796.67M | -43.67%397.87M | -5.78%426.64M | -69.25%140.23M | -7.27%1.98B | -25.94%363.73M | 17.18%706.26M | -25.42%452.79M |
| Net income continuous operations | -0.41%1.75B | -10.99%1.76B | 119.03%796.67M | -43.67%397.87M | -5.78%426.63M | -69.25%140.23M | -7.27%1.98B | -25.94%363.73M | 17.18%706.26M | -25.42%452.79M |
| Noncontrolling interests | -11.29%61.25M | 23.34%69.04M | 126.55%25.23M | -20.79%16.31M | 47.43%16.43M | -15.53%11.07M | 158.38%55.98M | 20.82%11.14M | 770.78%20.59M | 72.04%11.14M |
| Net income attributable to the company | 0.03%1.69B | -11.99%1.69B | 118.79%771.43M | -44.35%381.56M | -7.12%410.21M | -70.84%129.17M | -8.97%1.92B | -26.83%352.59M | 14.21%685.67M | -26.47%441.64M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 0.03%1.69B | -11.99%1.69B | 118.79%771.43M | -44.35%381.56M | -7.12%410.21M | -70.84%129.17M | -8.97%1.92B | -26.83%352.59M | 14.21%685.67M | -26.47%441.64M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 0.04%49.74 | -12.00%49.72 | 118.73%22.66 | -44.37%11.21 | -7.16%12.05 | -70.79%3.8 | -8.96%56.5 | -26.84%10.36 | 14.23%20.15 | -26.42%12.98 |
| Diluted earnings per share | 0.04%49.74 | -12.00%49.72 | 118.73%22.66 | -44.36%11.21 | -7.14%12.05 | -70.79%3.8 | -8.96%56.5 | -26.83%10.3598 | 14.21%20.146 | -26.44%12.9761 |
| Dividend per share | 0.00%20 | 0.00%20 | 0.00%10 | 0 | 0.00%10 | 0 | 5.26%20 | 0.00%10 | 0 | 11.11%10 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |